Physician profile
Paul Anthony Covello
NPI 1750624383
$15,915.18
in general payments reported to CMS, 2019-2025
10 companies · $12K in 2025
The $12K reported for 2025 was more than what 99% of Oral and Maxillofacial Surgery providers received nationally (typical 2025 total: $150).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,550 · 2020: $66.14 · 2021: $18.01 · 2022: $166 · 2023: $598 · 2024: $1,129 · 2025: $12K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $6,259 · Consulting Fee: $5,170 · Food and Beverage: $2,686.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $6,259.22 |
| Consulting Fee | $5,170.00 |
| Food and Beverage | $2,686.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medical Device Business Services, INC. | $11,997.10 | 2023-2025 | Trumatch |
| Axogen | $1,372.49 | 2019-2025 | Axoguard Nerve Connector, Avance Nerve Graft, Axoguard Nerve Cap |
| Inspire Medical Systems, INC. | $1,123.54 | 2023-2025 | Inspire |
| Kls-Martin L.P. | $678.74 | 2019-2025 | |
| Depuy Synthes Sales INC. | $349.02 | 2019-2025 | Matrixmidface, Trumatch, Matrixmandible |
| Janssen Biotech, INC. | $124.99 | 2025 | Rybrevant, Carvykti |
| Glaxosmithkline, LLC. | $121.77 | 2025 | Ojjaara |
| Integra Lifesciences Corporation | $63.00 | 2024 | Integra, Primatrix, Integra Dermal Regeneration Template |
| Zimmer Biomet Holdings, INC. | $51.81 | 2023 | Tmj System |
| Smith+Nephew, INC. | $32.72 | 2025 | Renasys Touch |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Covello listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.